Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.908
+0.007 (0.81%)
At close: Dec 24, 2024, 4:00 PM
0.907
0.00 (-0.04%)
After-hours: Dec 24, 2024, 4:29 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 137 employees as of December 31, 2023. The number of employees decreased by 79 or -36.57% compared to the previous year.
Employees
137
Change (1Y)
-79
Growth (1Y)
-36.57%
Revenue / Employee
$679,832
Profits / Employee
-$1,228,474
Market Cap
167.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Coherus BioSciences | 306 |
Seres Therapeutics | 233 |
Lyell Immunopharma | 224 |
TScan Therapeutics | 154 |
Nkarta | 150 |
Kyverna Therapeutics | 96 |
Solid Biosciences | 88 |
Fennec Pharmaceuticals | 29 |
NKTR News
- 17 days ago - Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting - PRNewsWire
- 5 weeks ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire
- 5 weeks ago - Multiple Catalysts Ahead For Nektar Therapeutics - Seeking Alpha
- 6 weeks ago - Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Nektar Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 6 weeks ago - Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 6 weeks ago - Nektar Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga